Information Provided By:
Fly News Breaks for September 14, 2018
ZGNX
Sep 14, 2018 | 06:16 EDT
BofA/Merrill analyst Tazeen Ahmad initiated Zogenix with a Buy and $63 price target saying lead asset, ZX008, could become a best-in-class treatment for pediatric epilepsies with a focus on Dravet Syndrome. Ahmad said there is an unmet need and is modeling world-wide peak sales of $3.4B, higher than peak sales achieved by other anti-epileptic drugs and anticonvulsants.
News For ZGNX From the Last 2 Days
There are no results for your query ZGNX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.